Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249196 | 0.92 | CRHR1 (0.52) | CRHR1CD38 | |
| SCHEMBL5249524 | 0.88 | CRHR1 (0.48) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL29405326 | 0.87 | CRHR1 (0.45) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL5250132 | 0.86 | CRHR1 (0.50) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL5250092 | 0.85 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5248198 | 0.84 | CRHR1 (0.49) | CRHR1CD38 | |
| SCHEMBL5250170 | 0.82 | CRHR1 (0.54) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL5248032 | 0.80 | CRHR1 (0.53) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL5250521 | 0.80 | CRHR1 (0.53) | CRHR1USP2LMNATSHRMAPK1 | |
| SCHEMBL5250222 | 0.77 | CRHR1 (0.49) | CRHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299378-B1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-6852732-B2 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | CRHR1, CRHR2, AGTR1 | CRHR1 1/4885USP2 4482/4885LMNA 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.